A new survival score for patients with brain metastases from non-small cell lung cancer

• Published in: Strahlentherapie und Onkologie 2013-09, Vol.189 (9), p.777-781
• Main Authors: Rades, D., Dziggel, L., Segedin, B., Oblak, I., Nagy, V., Marita, A., Schild, S.E., Trang, N.T., Khoa, M.T.
• Format: Article
• Language: English
• Subjects: Brain Neoplasms - mortality; Brain Neoplasms - radiotherapy; Brain Neoplasms - secondary; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - radiotherapy; Carcinoma, Non-Small-Cell Lung - secondary; Comorbidity; Female; Germany - epidemiology; Humans; Lung Neoplasms - mortality; Lung Neoplasms - therapy; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Prevalence; Radiotherapy; Radiotherapy, Conformal - mortality; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Survival Rate
• ISSN: 0179-7158; 1439-099X
• DOI: 10.1007/s00066-013-0362-x

Background and purpose Non-small cell lung cancer (NSCLC) is the most common primary tumor in patients developing brain metastasis. This study was performed to develop and validate a survival score particularly for this group of patients. Patients and methods In this study, the data of 514 patients treated with whole-brain radiotherapy (WBRT) alone for brain metastasis from NSCLC were retrospectively analyzed. The patients were divided into a test group (n = 257) and a validation group (n = 257). In the multivariate analysis of the test group, gender, performance status, and extracranial metastases were independent predictors of survival and, therefore, included in the scoring system. The score for each of the three factors was obtained from the 6-month survival rate (in %) divided by 10. The total scores that represented the sum of the three scores were 5, 8, 9, 11, 12, or 15 points. Three prognostic groups were formed according to the total scores. Results The 6-month survival rates in the test group were 9 % for 5–9 points (group A), 54 % for 11–12 points (group B), and 79 % for 15 points (group C). In the validation group the 6-month survival rates were 14, 56, and 78 %, respectively. The comparisons between the prognostic groups A, B, and C of the test and the validation group did not reveal any significant differences. Conclusion This new score appears valid and reproducible. It can help predict the survival of patients with brain metastasis from NSCLC.